866683-52-5

Usage

Uses

Used in Pharmaceutical Industry:
3-bromo-5-ethynylpyridine is used as a building block in organic synthesis for the development of pharmaceuticals. Its unique structure and reactivity allow for the creation of various drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-bromo-5-ethynylpyridine serves as a key intermediate in the synthesis of agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection.
Used in Functional Materials:
3-bromo-5-ethynylpyridine is utilized in the preparation of various functional materials. Its properties can be harnessed to develop materials with specific characteristics, such as conductivity or catalytic activity, for use in different industries.
Used in Fine Chemicals Manufacturing:
As an intermediate in the manufacturing of fine chemicals, 3-bromo-5-ethynylpyridine plays a crucial role in the production of specialty chemicals used in research, diagnostics, and other high-value applications. Its versatility in chemical reactions contributes to the synthesis of a diverse range of fine chemicals.

InChI:InChI=1S/C7H4BrN/c1-2-6-3-7(8)5-9-4-6/h1,3-5H

Upstream product

• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 639011-64-6 3-bromo-5-trimethylsilylethynylpyridine 

Downstream Products

• 866683-53-6 3-bromo-5-(4-fluorophenylethynyl)-pyridine 
• 866684-79-9 3-bromo-5-(3-trifluoromethylphenylethynyl)-pyridine 

Relevant academic research and scientific papers

Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A, X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

B-RAF KINASE INHIBITORS

The present invention encompasses compounds of general formula (1) where in the groups R0to R3 and L are defined as in claim 1, which are suitable for the 5 treatment of diseases characterised by excessive or abnormal cell proliferat

NEW CHEMICAL COMPOUNDS

The present invention relates to new compounds of general formula (I), wherein the groups R1 to R3, X1, X2, X3 and L1 are defined as in claim 1, which are suitable for the treatment of dise

PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS

The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C1-C4 alkyl, C1-C4 alkoxy, C1-C5 acyl, halo, amino, nitro, cyano, hydroxy, C1-C5 acylamino, C1-C4 alkylsulfonylamino, mono-, di- or trifluorinated C1-C3 alkyl, substituents which may be the same or different and may bear a CONH2, CONHCH3, CON(CH3)2, CO2H, CO2CH3, OCF3, CH2NHCOCH3, CH2NH2, CH2N(CH3)2, CH2CN, CH2OH, CH2NHSO2CH3, CH2N(CH3)(CH2)2 CN, CH2N(CH3)CH(CH3)2, CH2NHCH(CH3)2, CH2NH(CH2)2CH3, CH2NHCO2R4, CH2NHCH2CH3, CH2NHCH3 NHCOC(CH3)2, or N(S(O)2CH3)2 substituent; R1 is hydrogen, halo, R4, CN, C(NOH)R3, C(NO-R4)R3, (CH)2CO2R4 , (CH2)n OR3 , COR3 , CF3,SR4 , S(O)R4, S(O)2R4, COCH2CO2R3 , NHSO2R4 , NHCOR3, C(NOR3)NH2, CH2OCOR3,(CH2)n NH2, CON(CH3)2 (CH2)nNHCO2R4 , CO2R3, CONH2, CSNH2, C(NH)NHOR3, (CH2)nN(CH3)2, or CONHNHCOR3; R2 is 1,2-ethenediyl or 1,2-ethynediyl; R3 is hydrogen or C1-C4 alkyl; R4 is C1-C4 alkyl; and n is 0, 1, 2,3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.